|
Are You Bereaved? Journal of Clinical Oncology, Volume 44, Issue 1, Page 66-67, January 2026. <br/> 2026-01-01T08:00:00Z Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 Journal of Clinical Oncology, Volume 44, Issue 1, Page 54-65, January 2026. <br/> 2026-01-01T08:00:00Z Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer Journal of Clinical Oncology, Volume 44, Issue 1, Page 31-41, January 2026. <br/> 2026-01-01T08:00:00Z Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial Journal of Clinical Oncology, Volume 44, Issue 1, Page 20-30, January 2026. <br/> 2026-01-01T08:00:00Z Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study Journal of Clinical Oncology, Volume 44, Issue 1, Page 42-53, January 2026. <br/> 2026-01-01T08:00:00Z Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial Journal of Clinical Oncology, Volume 44, Issue 1, Page 9-19, January 2026. <br/> 2026-01-01T08:00:00Z If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not Journal of Clinical Oncology, Volume 44, Issue 1, Page 5-8, January 2026. <br/> 2026-01-01T08:00:00Z Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML? Journal of Clinical Oncology, Volume 44, Issue 1, Page 68-68, January 2026. <br/> 2026-01-01T08:00:00Z Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma Journal of Clinical Oncology, Volume 44, Issue 1, Page 71-71, January 2026. <br/> 2026-01-01T08:00:00Z Reply to: Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML? Journal of Clinical Oncology, Volume 44, Issue 1, Page 68-70, January 2026. <br/> 2026-01-01T08:00:00Z Carboplatin for Premenopausal Triple-Negative Breast Cancer: Time to Rethink the Neoadjuvant Standard? Journal of Clinical Oncology, Volume 44, Issue 1, Page 1-4, January 2026. <br/> 2026-01-01T08:00:00Z Mother's Grief Journal of Clinical Oncology, Ahead of Print. <br/> North Star Journal of Clinical Oncology, Ahead of Print. <br/> A Chance to Heal With Cold Hard Steel Journal of Clinical Oncology, Ahead of Print. <br/> Final Silence Journal of Clinical Oncology, Ahead of Print. <br/> Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity Journal of Clinical Oncology, Ahead of Print. <br/> |
An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II
New England Journal of Medicine, Volume 394, Issue 1, Page 39-50, January 1, 2026.
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab New England Journal of Medicine, Volume 394, Issue 1, Page 51-61, January 1, 2026.
Cardiogenic Shock New England Journal of Medicine, Volume 394, Issue 1, Page 62-77, January 1, 2026.
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction New England Journal of Medicine, Volume 394, Issue 1, Page 96-98, January 1, 2026.
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia New England Journal of Medicine, Volume 394, Issue 1, Page 98-100, January 1, 2026.
Direct-Acting Antiviral Agents in Hepatitis C–Associated Indolent Lymphomas New England Journal of Medicine, Volume 394, Issue 1, Page 93-96, January 1, 2026.
Navigating the Evolving Landscape of EGFR-Mutated NSCLC New England Journal of Medicine, Volume 394, Issue 1, Page 87-91, January 1, 2026.
Closing the Gap New England Journal of Medicine, Volume 394, Issue 1, Page 79-85, January 1, 2026.
Congenital Zika Syndrome New England Journal of Medicine, Volume 394, Issue 1, January 1, 2026.
Where Do I Put This? New England Journal of Medicine, Volume 394, Issue 1, Page 9-11, January 1, 2026.
Statistics in Medicine — What’s in an Estimand? New England Journal of Medicine, Volume 394, Issue 1, Page 6-9, January 1, 2026.
RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults New England Journal of Medicine, Ahead of Print.
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer New England Journal of Medicine, Ahead of Print.
Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD New England Journal of Medicine, Ahead of Print.
Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction New England Journal of Medicine, Ahead of Print.
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy New England Journal of Medicine, Ahead of Print.
Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents New England Journal of Medicine, Ahead of Print.
A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D New England Journal of Medicine, Ahead of Print.
Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years New England Journal of Medicine, Ahead of Print.
A Multicomponent Intervention to Improve Maternal Infection Outcomes New England Journal of Medicine, Ahead of Print.
Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia New England Journal of Medicine, Ahead of Print.
Prime Editing for p47phox-Deficient Chronic Granulomatous Disease New England Journal of Medicine, Ahead of Print.
Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults New England Journal of Medicine, Ahead of Print.
Ianalumab plus Eltrombopag in Immune Thrombocytopenia New England Journal of Medicine, Ahead of Print.
Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis New England Journal of Medicine, Ahead of Print.
An Evidence-Based Approach to Covid-19 Vaccination New England Journal of Medicine, Ahead of Print.
Fish Oil for Patients Receiving Hemodialysis — Red Herring or Great Catch? New England Journal of Medicine, Ahead of Print.
Digital Exhaust or Digital Gold? The Value of AI-Generated Clinical Visit Transcripts New England Journal of Medicine, Ahead of Print.
The 25th Anniversary of a Nearly Unknown Health Policy Turning Point New England Journal of Medicine, Ahead of Print.
|
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
In EGFR-mutated non–small-cell lung cancer, first-line osimertinib plus platinum–pemetrexed extended overall survival to 47.5 months, as compared with 37.6 months with osimertinib alone, but increased the risk of adverse events. 2026-01-01
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC In EGFR-mutated advanced non–small-cell lung cancer with progression after EGFR-TKI therapy, sacituzumab tirumotecan led to better progression-free and overall survival outcomes than chemotherapy. 2026-01-01
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab In drug-resistant extramedullary myeloma, dual treatment with talquetamab and teclistamab produced a response in 79% of patients, and 12-month overall survival was 74%; however, grade 3 or 4 adverse events were common. 2026-01-01
Where Do I Put This? Grieving over a beloved patient who’d invited her into the private, sacred space of her planned day of death, a palliative care physician finds it hard to switch gears as she sits in a PTA meeting. 2026-01-01
Navigating the Evolving Landscape of EGFR-Mutated NSCLC Combination chemotherapy has long been a mainstay of cancer treatment, although early mechanism-based therapies showed little promise. In 1970, Vincent T. DeVita and colleagues revolutionized oncology with their finding that combination regimens could induce long-term remission in patients with Hodgkin’s disease, even at advanced stages.1 More than 50... 2026-01-01
Direct-Acting Antiviral Agents in Hepatitis C–Associated Indolent Lymphomas In an update of the BArT study, direct-acting antivirals led to durable responses in HCV-associated indolent B-cell lymphomas, with 6-year progression-free survival of 66% and no relapses after a complete response. 2026-01-01
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. 2025-12-18
Noninferiority of One HPV Vaccine Dose to Two Doses In this trial, one dose of an HPV vaccine was noninferior to two doses in preventing HPV type 16 or 18 infection. 2025-12-18
Evidence to Action — Single-Dose HPV Vaccination and Cervical HPV Infection Kreimer and colleagues now report in the Journal1 the results of the ESCUDDO trial, which showed that the efficacy of a single dose of either a bivalent human papillomavirus (HPV) vaccine or a nonavalent formulation was similar to that of the standard two-dose schedule. This randomized trial... 2025-12-18
Reducing Tobacco Use Worldwide: The Epidemic of Tobacco Harms among People with Mental Health Conditions High rates of tobacco use among people with mental health conditions contribute to their increased morbidity and mortality, but tobacco cessation interventions can be effective in this population. 2025-12-18
Merkel-Cell Carcinoma A 72-year-old woman presented with a 3.5-month history of an enlarging, painless lump on her cheek. Examination showed a dome-shaped, reddish nodule on the left cheek, with a shiny surface and central hemorrhagic crust. 2025-12-18
ctDNA-Guided Therapy in Bladder Cancer — Ready? Liquid-biopsy analysis for circulating tumor DNA (ctDNA) has the potential to transform cancer care through personalized, noninvasive disease monitoring. In bladder cancer, ctDNA is a strong prognostic biomarker after cystectomy and may guide adjuvant treatment decisions. Retrospective and prospective studies show that ctDNA positivity is linked to an increased risk... 2025-12-18
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer In HER2-expressing urothelial cancer, disitamab vedotin plus toripalimab doubled the median progression-free survival, increased the median overall survival, and reduced adverse events as compared with chemotherapy. 2025-12-11
Understanding How Aspirin Prevents Metastasis A new study shows that aspirin enhances antimetastatic immunity by decreasing platelet activation, thereby releasing T cells from suppression by thromboxane A2. 2025-12-11
Disitamab Vedotin plus Toripalimab — New Players in Urothelial Carcinoma For decades, platinum-based chemotherapy was the standard first-line treatment for locally advanced or metastatic urothelial carcinoma.1 However, the treatment landscape in urothelial carcinoma has shifted with the advent of immune checkpoint inhibitors.2 Although immune checkpoint inhibitors were initially used as single agents after chemotherapy failure, combinations... 2025-12-11
Molecular Evidence of Multiorgan Damage in Patients with Immune-Related Adverse Events In 6 of 14 patients receiving immune checkpoint inhibitors, cell-free DNA methylation profiling revealed multiorgan damage with immune-related adverse events, often before symptoms appeared. 2025-12-11
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan improved invasive disease–free survival but carried a risk of interstitial lung disease. 2025-12-10
Ianalumab plus Eltrombopag in Immune Thrombocytopenia In a phase 3 trial, ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag, with a stable platelet response at 6 months in a higher percentage of patients with 9 mg/kg of ianalumab than with placebo. 2025-12-09
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma In relapsed or refractory multiple myeloma, teclistamab plus daratumumab significantly prolonged progression-free survival as compared with DPd or DVd (83.4% vs. 29.7%) and had higher response rates. 2025-12-09
Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia In relapsed or refractory T-cell acute lymphoblastic leukemia, off-the-shelf allogeneic base-edited CAR7 T cells mediated responses in 11 patients, enabling stem-cell transplantation in 9 patients in deep remission. 2025-12-08
|
|
| ||
|
[Editorial] Cancer consequences of the HIV funding crisis
Reductions in development assistance funding by previous major donors—the USA, the UK, France, and Germany—have led to substantial challenges to global HIV control in 2025. Against this stark backdrop, World AIDS Day 2025 was commemorated globally on Dec 1, 2025. UNAIDS released a report ahead of the day detailing the impact of the unprecedented changing international aid landscape on global HIV control programmes worldwide, particularly in low-income and middle-income countries. Failure to meet the 2030 global HIV targets could result in an additional 3·3 million new HIV infections between 2025 and 2030, according to the report. Thu, 01 Jan 2026 00:00:00 -0800
[Comment] Is PORTEC-4a the tipping point in endometrial cancer management? The PORTEC-4a trial1 provides, to the best of our knowledge, the first prospective, randomised evidence that a molecular integrated risk profile can safely guide adjuvant therapy decisions in high-intermediate risk endometrial cancer, reinforcing the rationale for incorporating molecular classification into clinical practice. According to Anne Sophie V M van den Heerik and colleagues’ findings in the Lancet Oncology,2 a refined molecular stratification supports a more tailored adjuvant treatment, enabling either de-escalation or intensification of radiotherapy based on individual tumour biology. Thu, 01 Jan 2026 00:00:00 -0800
[Comment] Micrometastatic axillary disease after neoadjuvant treatment In The Lancet Oncology, Giacomo Montagna and colleagues1 report the results of the large international retrospective OPBC-07/microNAC study, comparing the oncological outcomes and 3-year axillary recurrence rate for 1585 patients with breast cancer and residual micrometastases at axillary staging after neoadjuvant chemotherapy with and without completion axillary lymph node dissection (ALND). The feasibility and safety of axillary surgery de-escalation in patients with breast cancer who are at high risk of arm morbidity after ALND is an important clinical question. Thu, 01 Jan 2026 00:00:00 -0800
[Comment] The importance of preventing occupational cancer Cancer is a leading cause of death globally, and the number of cancer cases is rising in most countries. This increase presents a substantial challenge for health systems across the globe, as extensive resources are required for the diagnosis and treatment of cancer patients. Fri, 05 Dec 2025 23:30:01 +0000
[Comment] Has the limit been reached in treatment of unresectable oesophageal squamous cell carcinoma? SKYSCRAPER-08, a randomised, double-blind, placebo-controlled, phase 3 trial, marks a milestone in the treatment of oesophageal squamous cell carcinoma.1 Patients were randomly assigned to receive tiragolumab (a TIGIT inhibitor) plus atezolizumab (a PD-L1 inhibitor) and chemotherapy (paclitaxel and cisplatin) or to receive placebo and chemotherapy. Median progression-free survival was 6·2 months (95% CI 5·7–7·2) with tiragolumab plus atezolizumab versus 5·4 months (4·4–5·5) without (hazard ratio [HR] 0·56, 95% CI 0·45–0·70; p<0·0001), whereas median overall survival was 15·7 months (95% CI 13·3–20·4) versus 11·1 months (9·6–13·6; HR 0·70, 95% CI 0·55–0·88; p=0·0024). Thu, 01 Jan 2026 00:00:00 -0800
[Comment] Artificial intelligence in pancreatic cancer detection: from premise to practice Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest cancers globally, primarily because symptoms typically appear at a late stage, resulting in diagnosis when curative treatment is no longer possible. Furthermore, detection of PDAC and other periampullary cancers on CT scans is challenging and requires specialised radiological expertise. However, even experienced radiologists miss early-stage tumours on CT scans; in a 2023 study, 15 expert radiologists achieved an average sensitivity of just 79·6% when reading contrast-enhanced CTs for PDAC. Thu, 20 Nov 2025 23:30:04 +0000
[Comment] The promise of scalable symptom surveillance with stepped collaborative care in oncology Guidelines for managing deleterious symptoms from cancer and its treatments have been largely underused in practice. To address this problem, the National Cancer Institute launched the Improving the Management of Symptoms During and Following Cancer Treatment (IMPACT) consortium,1 an alliance of three research centres leading large-scale trials of electronic patient-reported outcome measure (ePROM) symptom surveillance and management systems. Andrea L Cheville and colleagues2 report findings from one IMPACT trial, showing positive effects of an enhanced, electronic health record (EHR)-facilitated cancer symptom control (E2C2) intervention on patients' and survivors' symptom burden and health-care use. Mon, 01 Dec 2025 23:30:03 +0000
[Comment] De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer HPV-associated oropharyngeal carcinoma has a distinct biology and responds favourably to primary radiation (and surgery)-based treatments. The long-term survival benefit is, however, offset by chronic detrimental impact on health-related quality of life for cancer survivors due to treatment-related toxic effects such as dysphagia and xerostomia. Consequently, many toxicity-mitigating de-escalation methods are being explored for HPV-associated oropharyngeal carcinoma.1 Minimally invasive primary transoral surgery followed by de-intensification of post-operative (chemo) radiation depending on pathological risk assessment is one such investigational approach. Thu, 01 Jan 2026 00:00:00 -0800
[Comment] Retraction and republication—De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer In September, 2025, The Lancet Oncology published results of the phase 3 MC1675 study on de-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma.1 After publication, the corresponding author alerted us to numerical errors present in table 1 caused by a mistranscription of the number of patients in each category of nodal staging by AJCC 7th edition staging and AJCC 8th edition staging. These errors did not affect other data, findings, or interpretation in the paper and we have thus corrected the online version as of Dec 22, 2025. Thu, 01 Jan 2026 00:00:00 -0800
[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer The ESPAC1 and ESPAC1-Plus trials in 2001 and 2004 respectively established surgery and six months of adjuvant chemotherapy as the standard of care for empirically resectable pancreatic cancer. This protocol was confirmed repeatedly over the last 25 years, leading to an enormous increase in the volume of patients being treated with surgery and adjuvant chemotherapy. The development of improved cancer treatment strategies requires that randomised controlled trials that aimed to be practice changing should include the best current standard of care as the control group. Thu, 01 Jan 2026 00:00:00 -0800
[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer We congratulate Quisette P Janssen and colleagues on the phase 3 PREOPANC-2 trial.1 PREOPANC-2 was the successor of the phase 3 PREOPANC-1, which showed improved overall survival following pre-operative chemoradiotherapy and surgery versus surgery for patients with anatomically resectable or borderline resectable pancreatic ductal adenocarcinoma. In light of the superiority for post-operative FOLFIRINOX versus gemcitabine and multiple rationales for pre-operative multi-agent chemotherapy, PREOPANC-2 tested the hypothesis that overall survival was longer following pre-operative FOLFIRINOX versus the gemcitabine-based chemoradiotherapy PREOPANC-1 approach. Thu, 01 Jan 2026 00:00:00 -0800
[Correspondence] The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer – Authors' reply We thank John P Neoptolemos and colleagues for their letter. They state that the ESPAC-1 trial set the standard of care for adjuvant therapy in resectable pancreatic cancer.1 However, ESPAC-1 set the standard of care for resected pancreatic cancer, including only those patients who had no occult metastases at surgery, underwent a resection, recovered from surgery, had no early recurrence, and remained fit for adjuvant treatment. In the adjuvant group of nine randomised controlled trials comparing neoadjuvant with adjuvant therapy, only 80% of all patients with resectable pancreatic cancer became patients with resected pancreatic cancer. Thu, 01 Jan 2026 00:00:00 -0800
[Correspondence] Tumour genetics and thyroid cancer staging We read with interest the Comment by Susan C Pitt and Megan Haymart1 on our Article on genetic modification of the American Joint Committee on Cancer (AJCC) staging system in papillary thyroid cancer2 and hold the following conservative opinions. Thu, 01 Jan 2026 00:00:00 -0800
[Corrections] Correction to Lancet Oncol 2025; 26: 187–99 van der Lei S, Puijk RS, Dijkstra M, et al. Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial. Lancet Oncol 2025; 26: 187–99—In this Article, all data labelled as IQR in the Summary, table 1 legend, and Results should have been labelled as range; figure 2 has also been updated. These corrections have been made to the online version as of Dec 22, 2025. Thu, 01 Jan 2026 00:00:00 -0800
[Corrections] Correction to Lancet Oncol 2025; 26: 1227–39 Ma D, Price K, Moore E, et al. De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2025; 26: 1227–39—In table 1 of this Article, the number of participants in each AJCC 8th edition N stage and AJCC 7th edition N stage at baseline have been corrected. This correction has been made as of Dec 22, 2025. Thu, 01 Jan 2026 00:00:00 -0800
[Corrections] Correction to Lancet Oncol 2025; 26: e477–87 Tang L-L, Huang C-L, Lin S-J, et al. Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas. Lancet Oncol 2025; 26: e477–87—In this Policy Review, the first sentence of Recommendation 3.3 should have read, “Posteriorly delineate the anterior third of the clivus (the cortex) if uninvolved (usually for T1 and T2 disease) and include the whole clivus (inferior, posterior column, up to the posterior clinoid process) for any clival involvement (usually for T3 and T4 disease).” This correction has been made to the online version as of Dec 22, 2025. Thu, 01 Jan 2026 00:00:00 -0800
[News] Carcinogenicity of atrazine, alachlor, and vinclozolin From October to November, 2025, a Working Group of 22 scientists from 12 countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of atrazine, alachlor, and vinclozolin. Fri, 21 Nov 2025 08:00:02 +0000
[News] Study links ultra-processed food consumption with bowel polyps in women younger than 50 years New research by Andrew T Chan (Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA) and colleagues published in JAMA Oncology shows that younger women (aged ≤50 years) who eat the highest proportions of ultra-processed foods (UPFs) are at a 45% increased risk of developing bowel polyps that can later develop into colorectal cancer. UPFs are novel branded products made from inexpensive industrial ingredients such as hydrogenated oils, protein isolates or glucose or fructose syrup, and cosmetic food additives (including dyes, artificial sweeteners, and emulsifiers). Thu, 20 Nov 2025 23:30:01 +0000
[News] WHO sets new global standard for child‑friendly cancer drugs On Nov 6, 2025, WHO published six new target product profiles for child‑friendly formulations of essential cancer medicines. The profiles aim to support the development of age‑appropriate formulations and close gaps in paediatric cancer care. Thu, 20 Nov 2025 23:30:01 +0000
[News] Europe is falling behind on targets to address AMR Antimicrobial resistance (AMR) is causing more than 35 000 deaths per year across Europe. According to estimates by the European Centre for Disease Prevention and Control (ECDC), based on 2024 data submitted by all countries in the EU and European Economic Area, Europe has met only one of five targets set to tackle the issue. Thu, 27 Nov 2025 23:30:04 +0000
[News] Gavi hits HPV vaccine milestone early but concerns surround future funding Gavi, the Vaccine Alliance, a public–private global health partnership with the goal of increasing access to immunisation in developing countries, is celebrating after working with lower-income countries to reach a key target to vaccinate millions of girls with the human papillomavirus (HPV) vaccine for cervical cancer in mid-November, 2025—6 weeks ahead of its original 3-year target. Thu, 27 Nov 2025 23:30:02 +0000
[News] New South Wales expands cancer coverage for firefighters On Nov 21, 2025, a ministerial media release announced a new legislation passed through Australian Parliament, expanding presumptive workers' compensation coverage for firefighters diagnosed with cancer. The new legislation extends the current list of 12 recognised malignancies in New South Wales, Australia, to include ten new cancers, including primary site lung, pancreatic, thyroid, and skin cancers. Reproductive cancers including cervical, ovarian, uterine, vaginal, vulval, and penile were also included. Thu, 27 Nov 2025 23:30:04 +0000
[News] UK–US drug pricing deal to cost NHS £3 billion as NICE increases new medicines threshold The UK has agreed a deal with the USA for a 0% tariff on pharmaceuticals in return for a 25% increase to the threshold at which the National Health Service (NHS) deems medicines to be cost-effective. Fri, 05 Dec 2025 23:30:01 +0000
[News] UK Government launches first Men's Health Strategy On Nov 19, 2025, the UK Government launched the first Men's Health Strategy for England. The policy paper noted that, over the past decade, healthy life expectancy for men has fallen by 1·5 years and that men in parts of the country with the most poverty die on average 10 years earlier than men in parts with the least poverty. Men are more likely than women to smoke, drink alcohol, or use drugs, and be overweight or have obesity. 19% of deaths in men over 35 years are attributable to smoking, seven percentage points higher than women in the same age group, and 68% of deaths from liver disease are in men. Thu, 11 Dec 2025 23:30:01 +0000
[Perspectives] Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK Cancer vaccines represent a transformative frontier in oncology, offering the potential to elicit durable and specific immune responses against tumour-associated or tumour-specific antigens. This technology has the potential to treat established malignancy, reduce tumour relapse, and even prevent cancer formation—improving survival outcomes. Advances in neoantigen discovery, mRNA vaccine platforms, and personalised immunotherapy have substantially enhanced the feasibility and efficacy of cancer vaccines across various malignancies. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial Individualised adjuvant treatment by molecular integrated risk profile is safe and effective for patients with high-intermediate risk endometrial cancer; it spared 46% of patients with a favourable profile from adjuvant treatment, and reduces both overtreatment and undertreatment. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study Vebreltinib showed antitumour activity in patients with MET amplification-driven advanced NSCLC who had previously received chemotherapy or were chemotherapy-naive. Further research is needed to validate these findings. Sat, 06 Dec 2025 08:00:01 +0000
[Articles] Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial Long-term follow-up confirms that radiotherapy followed by 12 cycles of adjuvant temozolomide without concurrent temozolomide during radiotherapy improves survival for individuals with aggressive IDHmt astrocytoma. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study Overall, these results do not support ALND for all patients with ypN1mi on sentinel lymph node biopsy treated with nodal radiotherapy; however, tumour biology should be taken into account when considering ALND omission. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial Nivolumab plus docetaxel did not improve progression-free survival or overall survival versus placebo plus docetaxel in patients with ARPI-pretreated, chemotherapy-naive mCRPC. These findings do not support the use of combinations of anti-PD-1 immune checkpoint inhibitors and docetaxel in the treatment of unselected populations of patients with ARPI-pretreated, chemotherapy-naive mCRPC. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Cancer mortality rates by detailed occupation among US working-age adults between 2020 and 2023: a population-based study US cancer mortality rates among working-age adults vary substantially by sex, occupation, and cancer site, suggesting workplace-related exposures beyond carcinogens. These findings highlight the need to study how working conditions, structural inequities, and health-care access influence cancer mortality risk by occupation. Fri, 05 Dec 2025 23:30:01 +0000
[Articles] First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial These results support the additional benefit of tiragolumab combined with atezolizumab and chemotherapy for patients with treatment-naive, locally advanced unresectable or metastatic oesophageal cancer. Further validation of tiragolumab plus atezolizumab and chemotherapy has been performed in the phase 3 SKYSCRAPER-08 trial (NCT04540211). Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial Independent review facility-assessed progression-free survival and overall survival were significantly better in the tiragolumab plus atezolizumab and chemotherapy group compared with chemotherapy alone for unresectable locally advanced, unresectable recurrent, or metastatic oesophageal squamous cell carcinoma. These data support the rationale for exploring dual checkpoint inhibition added to chemotherapy for this group of patients with a high unmet need. Thu, 01 Jan 2026 00:00:00 -0800
[Articles] Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study AI demonstrated substantially improved PDAC detection on routine CT scans compared to radiologists on average, showing potential to detect cancer earlier and improve patient outcomes. Thu, 20 Nov 2025 23:30:01 +0000
[Articles] Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial Centralised EHR-facilitated, symptom surveillance and collaborative care management are more beneficial than symptom surveillance alone in reducing the population burden of SPPADE symptoms in oncology patients. Mon, 01 Dec 2025 23:30:01 +0000
[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 1: intraoperative recommendations for mapping, monitoring, and decision making In adult patients with newly diagnosed or recurrent diffuse glioma, more extensive resection is associated with longer progression-free and overall survival. Intraoperative mapping techniques are used to safely increase the extent of resection by locating, monitoring, and preserving the function of potentially infiltrated brain during surgery. However, there is no consensus on the indications for intraoperative mapping, the optimal functional tests to be used intraoperatively, or intraoperative decision making. Thu, 01 Jan 2026 00:00:00 -0800
[Policy Review] A comprehensive framework for glioma surgery by the PIONEER Consortium and RANO resect group, part 2: perioperative recommendations for neurological, language, functional, and quality-of-life assessment Historically, the assessment of surgical outcomes in patients with glioma has been focused on technical outcomes, such as volumetric analysis of the residual tumour, progression-free survival, and overall survival. Other outcomes, such as neurological deficits, can be challenging to assess in an objective, quantifiable, and comprehensive manner. As a result, no consensus is available on methods to systematically evaluate perioperative neurological, language, cognitive, and functional outcomes in patients with glioma. Thu, 01 Jan 2026 00:00:00 -0800
[Policy Review] International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative Histopathologically detected extranodal extension leads to upstaging and treatment escalation in head and neck squamous cell carcinoma. There is considerable variation in the prevalence of histopathologically detected extranodal extension in comparable studies. The Head and Neck Cancer International Group, which includes 23 organisations managing patients with head and neck cancer, identified several challenges in evaluating histopathologically detected extranodal extension. Thus, the Head and Neck Consensus Language for Ease and Reproducibility (HN-CLEAR) and its global stakeholders prioritised developing diagnostic criteria and uniform terminology for histopathologically detected extranodal extension. Thu, 01 Jan 2026 00:00:00 -0800
[Review] Development of a core outcome set for adolescents and young adults with cancer Adolescents and young adults aged 15–39 years diagnosed with cancer are faced with unique challenges, which affect key developmental milestones and can create complex care needs. The aim of this study was to reach international consensus on the minimum set of outcomes to measure through the development of a core outcome set (COS). The COS development followed published methodological standards. A literature review and interviews with adolescents and young adults with cancer and health-care professionals generated a comprehensive list of 129 outcomes, spanning clinical and patient-reported outcomes relevant to adolescents and young adults with cancer. Thu, 01 Jan 2026 00:00:00 -0800
[Clinical Picture] High-output cardiac failure from a synovial sarcoma mimicking arteriovenous fistula A 30-year-old woman presented to the Vascular Anomalies Centre at Shanghai Ninth People's Hospital in February, 2021, for a worsening and painful left inguinal arteriovenous fistula, which had been diagnosis 7 years previously following a strain 10 years ago. Initial endovascular embolisation in 2014 provided only transient relief, with subsequent symptom recurrence, progressive deep vein thrombosis, limb oedema, and claudication. By 2018, she had developed orthopnoea indicative of cardiac failure and required continuous diuretics, having received only symptomatic care until her presentation. Thu, 01 Jan 2026 00:00:00 -0800
|
[Comment] Media coverage and PATHFINDER2: hype, simplification, and free advertising
The recent media coverage of interim results from the PATHFINDER2 study of GRAIL's Galleri multicancer detection blood test exemplifies a troubling and recurring trend in science communication: the commercially driven, premature framing of non-peer-reviewed data as proof of a transformative breakthrough. Released via an embargoed press statement on Oct 17, 2025, and then presented as a late-breaking abstract at the European Society for Medical Oncology (ESMO) Congress,1 the study's hand-picked performance metrics prompted a wave of enthusiastic, uncritical reporting across mainstream media outlets. 2025-12-22T23:30:01Z
[Articles] O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial FET-PET-based target volume delineation for re-irradiation did not lead to a significant clinical benefit compared with CE-T1MRI-based treatment in patients with recurrent glioblastoma. Thus, CE-T1MRI remains the preferred delineation method in this setting. 2025-12-19T23:30:01Z
[News] Progress in global tobacco control measures Global tobacco control measures have led to substantial decrease in the number of tobacco users—from 1·38 billion in 2000 to 1·20 billion in 2024, but there are concerns over possible undermining of these measures in some countries, due to untoward activities including illicit tobacco trade and interference of the tobacco industry in policy making. 2025-12-18T23:30:01Z
[News] San Antonio Breast Cancer Symposium 2025 In the phase 3 IidERA trial presented by Aditya Bardia (University of California Los Angeles, Los Angeles, CA, USA), adjuvant giredestrant, an oral selective oestrogen receptor degrader (SERD) showed significant improvement in invasive disease-free survival (iDFS) compared with standard-of-care endocrine therapy in patients with early-stage HR+ HER2– breast cancer. 4170 patients were randomly assigned (1:1) to receive either 30 mg of giredestrant or tamoxifen, letrozole, anastrozole, or exemestane. 2025-12-18T23:30:01Z
|
[Editorial] Acute myeloid leukaemia at the extremes
The past decade has seen advances for the treatment of acute myeloid leukaemia (AML), but challenges remain for those at the extremes of the disease, particularly for those older than 65 years, and paediatric patients. Therefore, the announcement on Oct 24, 2025, from the US Food and Drug Administration that expanded the approval of revumenib, a menin inhibitor, for the treatment of relapsed or refractory AML with NPM1 mutations in adult and paediatric patients 1 year and older is a welcome one. Mon, 01 Dec 2025 00:00:00 -0800
[Correspondence] Ferritin-guided iron supplementation in blood donors We congratulate Jan H M Karregat and colleagues on their excellent FORTE trial,1 which represents a substantial methodological advance in addressing the challenges identified in the 2014 Cochrane review on iron supplementation in blood donors.2 Mon, 01 Dec 2025 00:00:00 -0800
[Correspondence] Ferritin-guided iron supplementation in blood donors – Authors' reply We thank Tomohiko Sato and colleagues for acknowledging the quality and relevance of our FORTE trial1 and for highlighting the importance of compliance to iron supplementation strategies, potential legal obstructions to prescribing supplements, and cultural and educational factors as international implementation challenges. Their reflections underscore the broader implications of our findings and the need to consider local contexts when translating research into practice. The ferritin-guided iron supplementation approach evaluated in FORTE offers a robust, scalable model that addresses methodological gaps, protects donor health, supports a sustainable blood supply, and limits unnecessary interventions. Mon, 01 Dec 2025 00:00:00 -0800
[Correspondence] Menstrual blood loss reduction to control anaemia (and more) The belief that heavy menstruation is simply natural might seem unrelated to the orgasm gap or women often not being taken seriously when reporting pain. However, these issues tell a deeper story: women have internalised a societal message to normalise discomfort, neglect, or inequality—especially regarding their bodies and health. Mon, 01 Dec 2025 00:00:00 -0800
[In Focus] A communitarian approach to cell therapy and gene therapy access in low-income and middle-income countries In low-income and middle-income countries (LMICs), access to both existing and emerging therapies can be limited. Novel cell and gene therapies (CGT)—such as chimeric antigen receptor T-cell therapies for blood cancers and gene therapies for sickle cell disease—are particularly resource intensive. Expanding global access risks exacerbating resource constraints in LMICs due to high costs, complex manufacturing, and the need for extensive care-delivery infrastructure. Mon, 01 Dec 2025 00:00:00 -0800
[In Focus] Illegal blood trade as cause for blood shortages in public hospitals in northern Nigeria WHO recognises blood as an essential medicine, yet many regions face critical shortages. In sub-Saharan Africa, insufficient blood donations and concerns about blood safety exacerbate the problem. Recent calls for prioritising blood transfusion as a global health priority highlight the urgency of addressing these challenges. Here we report on illegal blood trade as a significant, under-reported factor threatening safe blood supply and contributing to preventable maternal and child mortality. Although locally affordable interventions can improve transfusion practices, increased repeat voluntary blood donation is crucial to meet the increasing demand. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial An intensification strategy guided by response and MRD deepened remissions in individuals with residual disease and spared early responders further treatment. This approach merits further study as an alternative to fixed-duration triplet therapy. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial The venetoclax plus azacitidine regimen showed a manageable safety profile and promising activity as salvage therapy for relapsed or refractory T-cell acute lymphoblastic leukaemia. Given the limited sample size and single-arm design nature, further confirmatory trials are warranted to validate its efficacy as a potential salvage therapy for relapsed or refractory T-cell acute lymphoblastic leukaemia. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study These results demonstrate that model-based ATG dosing promotes robust CD4+ immune reconstitution after ex vivo CD34+ selected allogeneic HCT, underscoring the potential of pharmacokinetically guided ATG as a strategy to optimise immune recovery in myeloablative, calcineurin inhibitor-free transplantation for haematological malignancies. Mon, 01 Dec 2025 00:00:00 -0800
[Articles] Motivators and barriers affecting decisions to participate in sickle cell disease clinical trials in the global Learning and Insights into Sickle Cell Trial Experiences (LISTEN) Survey: global and regional findings Balanced and tailored communication about clinical trials to the sickle cell disease community should be prioritised to optimise participation opportunities, thereby enhancing representation and generalisability of the results. Mon, 01 Dec 2025 00:00:00 -0800
[Viewpoint] Medical tourism for cellular therapy: a clinical perspective Medical tourism in the field of cellular therapy has been increasing exponentially, especially in the past decade, due to multiple advances in the field. Our Viewpoint explores this growing field, with a specific focus on haematopoietic stem-cell transplantation (HSCT) and chimeric antigen receptor (CAR) T-cell therapy. We discuss the global status, regulatory challenges, and ethical considerations associated with medical tourism. We highlight benefits and drawbacks of medical tourism with regard to patient care and the impact on local health-care systems. Mon, 01 Dec 2025 00:00:00 -0800
[Clinical Picture] Leprosy and leukaemia: an unexpected interaction A 64-year-old man first presented 6 years ago with multiple skin nodules, limb numbness, pain, and pruritus. Facial oedema developed 1 year later. An initial complete blood count showed leukocytosis and lymphocytosis (appendix p 1). Bone marrow aspiration established a diagnosis of chronic lymphocytic leukaemia and watchful waiting was instituted. Mon, 01 Dec 2025 00:00:00 -0800
|
|
| ||
|
Acalabrutinib to assail CLL in the frail
Volume 146, Issue 26 December 25 2025 Armed and SAVVY: CAR T cells combat AML Volume 146, Issue 26 December 25 2025 Matchmaking gene therapy with mimetic antibodies Volume 146, Issue 26 December 25 2025 Runx2 takes center stage in regulating HSC expansion Volume 146, Issue 26 December 25 2025 New approach targets key traffickers in the fibrosis network Volume 146, Issue 26 December 25 2025 LEF1 and CLL: a matter of quantity and quality Volume 146, Issue 26 December 25 2025 MPN predisposition: shared roots, split branches Volume 146, Issue 26 December 25 2025 Beyond Arg39: new insights into antiphospholipid antibodies Volume 146, Issue 26 December 25 2025 Feasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture? Immune checkpoint inhibition using antibodies blocking the action of programmed cell death protein 1 (PD1) is now standard therapy for patients with relapsed or refractory Hodgkin lymphoma (HL), and its use in combination regimens in first-line therapy increases efficacy. However, PD1 inhibitor use also brings automimmune toxicities, which need to be weighed against incremental efficacy. In this Blood Spotlight, Jaworek and Bröckelmann summarize what is known about these immune-related toxicities, emphasizing those which may persist, become chronic, or occur late. They contextualize how these toxicities need to be reported in trials and considered in weighing whether their benefits exceed their risks in first-line therapy for patients with HL who are highly curable with cytotoxic chemotherapy alone.
Volume 146, Issue 26 December 25 2025 Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial Many patients with chronic lymphocytic leukemia (CLL) are older (>80 years old) and/or frail, yet they are often not included in clinical trials. Simon and colleagues report a dedicated trial for such patients, investigating the Bruton tyrosine kinase inhibitor acalabrutinib as initial therapy. They report that while two-thirds experienced severe adverse events, efficacy was high, and more than half of patients recorded an improvement in their self-perceived frailty. This trial sets the benchmark for ongoing development of safer, more effective therapy for CLL in this population.
Volume 146, Issue 26 December 25 2025 CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia The efficacy of chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML) has been limited by several factors, including the lack of a universal target. Geyer et al report design of CAR T cells armed with interleukin-18 (IL-18) secretion that target CD371, a transmembrane glycoprotein with high expression on AML and leukemia-initiating cells. In a pilot study, 3 of the first 5 patients achieved remission, with single-cell analyses indicating that response is associated with expansion of CD8+ effector memory CAR T cells and with activation of endogenous natural killer cells, consistent with the hypothesis that IL-18 will increase both innate immunity and promote CAR T-cell cytotoxicity.
Volume 146, Issue 26 December 25 2025 Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody Could there be a better gene than the factor VIII (FVIII) gene to transfer for curative treatment of hemophilia A? Muczynski et al demonstrate stable correction of the bleeding diathesis in hemophilia A mice after gene therapy with an adeno-associated virus (AAV) vector encoding a novel single-chain FVIII-mimetic antibody, Bi8, expressed from hepatocytes. Similar to emicizumab, Bi8 binds FIX and FX simultaneously, enhancing FIXa-mediated FX activation. This novel approach, if translatable in clinical trials, may help overcome some of the limitations of currently approved hemophilia A gene therapies, including those in patients with FVIII-neutralizing antibodies.
Volume 146, Issue 26 December 25 2025 A genome-wide screen identifies Runx2 as a novel regulator of hematopoietic stem cell expansion and T-cell commitment In vitro expansion of hematopoietic stem cells (HSCs) remains a significant goal for cellular therapy. Using a genome-wide CRISPR knockout screen, Meaker and colleagues identify that the transcription factor Runx2 is a key negative regulator of HSC expansion and T-cell lineage commitment ex vivo and in vivo. These data add to our understanding of intrinsic regulation of HSC proliferation and fate determination while also suggesting strategies to apply this to augment various cellular therapies.
Volume 146, Issue 26 December 25 2025 Sclerotic GVHD and scleroderma share dysregulated gene expression that is ameliorated by EREG therapeutic antibody Volume 146, Issue 26 December 25 2025 Increased LEF1 protein levels and isoform switching drive cell proliferation in chronic lymphocytic leukemia Volume 146, Issue 26 December 25 2025 Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40 Most myeloproliferative neoplasms (MPNs) arise because of 1 of 3 distinct somatic mutations (JAK2, MPL, or CALR) affecting JAK-STAT signaling, yet their phenotypes are quite diverse and not readily explained by the specific driver mutation. Increasing evidence highlights germ line predisposition as a key modifier of MPN phenotypes. Tapper et al used genome-wide association analyses to identify germ line genetic determinants of MPN phenotypes and leverage this to refine genetic risk prediction.
Volume 146, Issue 26 December 25 2025 Domain and residue mapping of autoantibodies to β2GPI reveals differences among antiphospholipid syndrome phenotypes Antiphospholipid syndrome (APS) is an autoimmune disorder defined by the occurrence of thrombosis or pregnancy-associated complications in patients who are persistently positive for antiphospholipid antibodies, many of which bind the plasma protein β2-glycoprotein I (β2GPI). By analyzing antibodies from 52 patients with APS and performing structure-based mutational studies, Kumar et al showed that these autoantibodies recognize 2 distinct epitopes in the first domain of the protein. Their work challenges the prevailing view of a single pathogenic “hot spot,” provides mechanistic insight into how these antibodies engage their target, and begins to allow association of different APS clinical phenotypes with epitope specificity.
Volume 146, Issue 26 December 25 2025 NMNAT3 deficiency: a novel red blood cell enzymopathy causing hemolysis by altering NAD levels and glycolysis Volume 146, Issue 26 December 25 2025 Babesiosis precipitating immune thrombotic thrombocytopenic purpura Volume 146, Issue 26 December 25 2025 Asquith NL, Carminita E, Camacho V, et al. The bone marrow is the primary site of thrombopoiesis. Blood. 2024;143(3):272-278. Volume 146, Issue 26 December 25 2025 Silkenstedt E, Dreyling M. Treatment of relapsed/refractory MCL. Blood. 2025;145(7):673-682. Volume 146, Issue 26 December 25 2025 Volume 146, Issue 26 December 25 2025 |
Proteomic Analysis of Golden Sputum Reveals Pulmonary Complement Activation During Acute Chest Syndrome in Children With Sickle Cell Disease
Tue, 30 Dec 2025 23:51:54 -0800 Extramedullary Disease—Achilles Heel in Myeloma? Mon, 29 Dec 2025 20:47:42 -0800 Primary Breast MALT Lymphoma: Clinical Features and Outcomes From a Single‐Institution Experience at Mayo Clinic Mon, 29 Dec 2025 20:46:04 -0800 Plasma Exchange and Eculizumab Treatment of a Child With Sickle Cell Disease, Severe Intravascular Hemolysis, Macrophage Activation, and Multiple Organ Failure Mon, 29 Dec 2025 20:45:21 -0800 Can We Really Believe This Platelet Count? Sat, 27 Dec 2025 04:03:07 -0800 Correction to “Budesonide, Added to PTCy‐Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation” Sat, 27 Dec 2025 03:04:58 -0800 Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS‐COV‐2—A Report From the EPICOVIDEHA/EPIRESEHA Registry Wed, 24 Dec 2025 03:29:43 -0800 Economic Burden of Sickle Cell Disease: A Retrospective Study of Pediatric and Adult Individuals With Medicaid Coverage From 2016 to 2020 Wed, 24 Dec 2025 00:00:00 -0800 Acute Exercise Challenge and Airway Dynamics in Youth With Sickle Cell Anemia: A Multicenter Study Sat, 20 Dec 2025 22:24:18 -0800 A Combination of Plerixafor and Filgrasting Promotes Successful CD34+ Cell Collection for CRISPR/Cas9 Therapy in Sickle Cell Disease Patients With Insufficient Response to Plerixafor Alone Fri, 19 Dec 2025 02:40:55 -0800 Basiliximab in the Prophylaxis of aGVHD for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: A Prospective, Multicenter, Open‐Label, Randomized Controlled Study Fri, 19 Dec 2025 00:19:28 -0800 Autoimmune Features in Sickle Cell Patients: A New Explanation for Liver Damage? Tue, 16 Dec 2025 02:21:46 -0800 Real‐World Outcomes and Treatment Patterns in Patients With Acute Myeloid Leukemia and TP53 Gene Mutation or 17p Deletion Sat, 13 Dec 2025 01:15:13 -0800 Long‐Term Outcomes of a Stratified Treatment Regimen Based on Etoposide and Glucocorticoids in Children With Hemophagocytic Lymphohistiocytosis (CCHG‐HLH‐2018): A Multicenter, Single‐Arm Clinical Study Fri, 12 Dec 2025 00:00:00 -0800 Extending the Biological Axis Linking CHIP to Cancer Emergence Tue, 09 Dec 2025 21:36:17 -0800 Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial Tue, 09 Dec 2025 20:50:54 -0800 Clinical Spectrum of Noonan Syndrome–Associated Myeloproliferative Disorder Sun, 07 Dec 2025 19:32:03 -0800 Reversal of Echocardiographic Alterations Following Hematopoietic Stem Cell Transplantation in Children With Sickle‐Cell Anemia Sun, 07 Dec 2025 00:00:00 -0800 DIA Regimen Versus IA Regimen for Induction Therapy in Younger Adults With Acute Myeloid Leukemia: A Multicenter Open‐Label Randomized Controlled Trial Sat, 06 Dec 2025 10:14:39 -0800 Non‐T‐Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT Sat, 06 Dec 2025 10:08:55 -0800 Why We Do Not Recommend That People With High‐Risk Smoldering Myeloma Receive Treatment Thu, 04 Dec 2025 22:26:06 -0800 |
Issue Information
December 2025 Diagnosing deep vein thrombosis: a new strategy for an old problem December 2025 Thrombin, tissue factor pathway inhibitor, and von Willebrand factor: unmasking the coagulopathy of veno-venous extracorporeal membrane oxygenation December 2025 Soluble platelet activation markers in coronary artery disease: a step toward precision thrombosis risk assessment? December 2025 When genotype and phenotype disagree: rethinking thrombophilia testing in the genomic era December 2025 “Perioperative management of direct oral anticoagulants in patients having a high-bleed–risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot randomized trial”: comment from Pak et al. December 2025 “Perioperative management of direct oral anticoagulants in patients having a high-bleed–risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation 2 pilot randomized trial”: reply December 2025 “Health-related quality of life in children with von Willebrand disease: results of the French real-life Willebrand Study Health-related Quality of Life study”: comment December 2025 “Health-related quality of life in children with von Willebrand disease: results of the French real-life Willebrand Study Health-related Quality of Life study”: reply December 2025 “Recombinant a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS-13) for acute and prophylactic treatment of congenital thrombotic thrombocytopenic purpura in pregnancy”: comment December 2025 |
|
| ||
|
Celebrating a year of ASH Scholar awardees December 23 2025 - Volume 9, Issue 24 Emicizumab in infants: not just cost-effective but mandatory December 23 2025 - Volume 9, Issue 24 Abatacept today, TMA away: protecting the endothelium December 23 2025 - Volume 9, Issue 24 A new sUSPect in T-ALL risk stratification December 23 2025 - Volume 9, Issue 24 Sickle cell disease and thalassemia go to the PROm December 23 2025 - Volume 9, Issue 24 Challenges and opportunities for improvement in the practical management of adults with acute lymphoblastic leukemia December 23 2025 - Volume 9, Issue 24 Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease December 23 2025 - Volume 9, Issue 24 Antibody-DNA nanostructure conjugates integrate doxorubicin and rituximab to enhance therapeutic efficacy for DLBCL December 23 2025 - Volume 9, Issue 24 Clinical applications of mass spectrometry in multiple myeloma December 23 2025 - Volume 9, Issue 24 Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going December 23 2025 - Volume 9, Issue 24 Predictive markers for the efficacy of CAR T-cell therapy: the interplay between CAR T-cell fitness and systemic immunity December 23 2025 - Volume 9, Issue 24 Applying principles of vaccine development to oncomicrobial vaccines December 23 2025 - Volume 9, Issue 24 Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis December 23 2025 - Volume 9, Issue 24 Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study December 23 2025 - Volume 9, Issue 24 Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML December 23 2025 - Volume 9, Issue 24 Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel December 23 2025 - Volume 9, Issue 24 Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel December 23 2025 - Volume 9, Issue 24 Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study December 23 2025 - Volume 9, Issue 24 In situ gene editing of hematopoietic stem cells via AAV-delivered CRISPR guide RNAs December 23 2025 - Volume 9, Issue 24 Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe December 23 2025 - Volume 9, Issue 24 SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma December 23 2025 - Volume 9, Issue 24 Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras December 23 2025 - Volume 9, Issue 24 Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration December 23 2025 - Volume 9, Issue 24 Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma December 23 2025 - Volume 9, Issue 24 Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis December 23 2025 - Volume 9, Issue 24 Androgen receptor signaling as a new target for intervention in acute myeloid leukemia December 23 2025 - Volume 9, Issue 24 Combining drugs that bypass p53 to treat TP53-mutated leukemias December 23 2025 - Volume 9, Issue 24 Critical role of niche S100A8 for acute myeloid leukemia progression and hematopoiesis regeneration December 23 2025 - Volume 9, Issue 24 A novel isoform of tensin-1 promotes actin filament assembly for efficient erythroblast enucleation December 23 2025 - Volume 9, Issue 24 Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis December 23 2025 - Volume 9, Issue 24 Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction December 23 2025 - Volume 9, Issue 24 Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies December 23 2025 - Volume 9, Issue 24 Abatacept improves posttransplant survival and reduces endothelial injury syndromes in β-thalassemia major December 23 2025 - Volume 9, Issue 24 Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation December 23 2025 - Volume 9, Issue 24 Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma December 23 2025 - Volume 9, Issue 24 Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL December 23 2025 - Volume 9, Issue 24 USP7 alterations are associated with a poor survival in pediatric T-cell acute lymphoblastic leukemia December 23 2025 - Volume 9, Issue 24 A patient-derived CABIN1 mutation recapitulates features of idiopathic multicentric Castleman disease in a mouse model December 23 2025 - Volume 9, Issue 24 Time to redefine HHV-8 MCD and KICS criteria? December 23 2025 - Volume 9, Issue 24 Bond DA, Switchenko JM, Villa D, et al. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 2021;5(23):5179-5189. December 23 2025 - Volume 9, Issue 24 Greenbaum U, Strati P, Saliba RM, et al. CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicity. Blood Adv. 2021;5(14):2799-2806. December 23 2025 - Volume 9, Issue 24 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
|
|
| ||
|
|
Frequency and face validity of reported family history of cancer in first‐degree relatives and genetic syndromes among children with cancer in Project:EveryChild: A report from the Children’s Oncology Group
Despite limitations and the need for manual curation, FH and GS data collected by using proposed questions were sufficient to identify known heritable cancer patterns. These findings support questionnaire‐based data collection and highlight areas for improvement. Sun, 28 Dec 2025 21:45:48 -0800 Metabolic obesity phenotypes and breast cancer risk before and after menopause: A nationwide cohort study in South Korea After menopause, obesity was associated with elevated breast cancer risk, which was further increased by metabolic syndrome. In contrast, no elevated risk was observed before menopause. The current findings highlight differences in breast cancer risk by menopausal status across metabolic obesity phenotypes, emphasizing the need for targeted prevention strategies and further research into underlying mechanisms. Sun, 28 Dec 2025 21:40:01 -0800 Impact of the Area Deprivation Index on stage at diagnosis in penile squamous cell carcinoma: A statewide cohort analysis Greater neighborhood‐level socioeconomic deprivation is associated with advanced‐stage disease at penile cancer diagnosis. These findings emphasize the role of social determinants in disease presentation, and may guide targeted interventions in disadvantaged populations. Sun, 28 Dec 2025 21:37:53 -0800 Molecular alteration profiles characterize intraductal carcinoma of the prostate IDC‐P possesses a distinct molecular and immunological profile. Understanding these molecular underpinnings is crucial for the development of personalized treatment strategies for histologically distinct prostate cancer subsets. Sun, 28 Dec 2025 21:29:10 -0800 Associations of lifetime exposure to fine particulate matter (PM2.5) and its constituents with increased risk and earlier occurrence of 14 site‐specific cancers Lifetime exposure to PM2.5 and its constituents might increase the risk and accelerate the onset of various cancers. Combustion‐sourced and agriculture‐sourced components mainly account for this influence, with the middle‐aged and elderly life stage (aged 45 years and older) a sensitive exposure window. Sun, 28 Dec 2025 01:12:44 -0800 Patterns of lung cancer incidence in adults diagnosed under age 50 in the United States, 2000–2021 Early‐onset lung cancer incidence declined overall from 2000 to 2021, except for persistent or rising LUAD among Asian and Hispanic females, which implicates emerging non‐tobacco risk factors and highlights the need for targeted prevention. Wed, 24 Dec 2025 09:10:28 -0800 Customized early detection of colorectal cancer in Nigeria identifies advanced adenomas and early‐stage disease Combining community engagement with patient navigation significantly increased CRC awareness and enabled the detection of advanced adenomas and early‐stage cancers. Expanding this model to a national level is recommended to evaluate broader impact, cost‐effectiveness, and potential implementation challenges. Mon, 22 Dec 2025 00:01:02 -0800 Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials In this study, the authors did not find any evidence of difference in the treatment effect of apalutamide on OS across patients of different races, although interpretation remains limited by poor representation of racial minorities. Among apalutamide‐treated patients, there was no association of race with OS. Sat, 20 Dec 2025 08:43:53 -0800 Correction to “Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly” Sat, 20 Dec 2025 08:39:49 -0800 Exploring hospital volume thresholds for improved sarcoma treatment across different age categories in the United States Fri, 19 Dec 2025 09:35:13 -0800 Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study These findings emphasize the independent prognostic relevance of chromosome 5/5q losses underscoring the clinical relevance of cytogenetic testing for −5/5q even in this high‐risk cohort. Fri, 19 Dec 2025 09:29:58 -0800 Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials Rigid eligibility criteria exclude stable patients who might benefit from investigational treatments. Easing criteria related to incidental or asymptomatic laboratory abnormalities could broaden trial accessibility and improve enrollment in populations that are more representative of real‐world use. Fri, 19 Dec 2025 09:25:13 -0800 Characterizing the burden of care for children with solid tumors in the United States: A cross‐sectional analysis from the Child Health Evaluation of Surgical Services Group Children with solid tumors experience a high number of medicalized days in the first year after diagnosis. Furthermore, the number of medicalized days has increased over the last decade. Quantifying medicalized days provides a way to track the social and economic burdens of care. Better understanding of this care burden may provide an opportunity for physicians, patient advocates, and policymakers to address the financial toxicity of treatment. Thu, 18 Dec 2025 09:30:13 -0800 Meaningful differences and changes for five Patient‐Reported Outcomes Measurement Information System domains in a large cohort of patients with cancer PROMIS computer‐adaptive test measures of pain, fatigue, anxiety, depression, and physical function are sensitive to group differences and changes over time. Regular symptom monitoring in conjunction with the recommended thresholds could be useful in research and clinical settings. Thu, 18 Dec 2025 09:24:26 -0800 Issue Information Thu, 18 Dec 2025 09:09:41 -0800 |
|
|
| ||
|
|
Real-World Endpoints in Stereotactic Body Radiation Therapy Trials for Oligoprogression: Beyond Progression-Free Survival and Overall Survival
Oligoprogressive disease is a clinically distinct scenario, characterized by limited progression (typically 1-5 metastatic sites), during otherwise effective systemic therapy, where the majority of disease sites remain controlled. This can occur in the context of either widespread or limited disease.1 Earlier identification of oligoprogression is becoming more common due to advances in diagnostic and imaging technology. As systemic therapies become more effective and better tolerated, clinicians and their patients are increasingly reluctant to switch treatments based on limited progression, viewing such lesions as potentially treatment-resistant subclones that benefit from locally ablative therapy, until progression becomes more extensive.
Mon, 29 Dec 2025 00:00:00 -0800 Skull Dosimetry for Mitigating Acute Hematologic Toxicity in NSCLC Patients with Brain Metastases Undergoing Cranial Radiotherapy and Immunotherapy Brain radiotherapy (RT) combined with immunotherapy is standard for non-small cell lung cancer (NSCLC) patients with brain metastases. However, RT-induced hematologic toxicities (HTs) can cause treatment interruption and lymphopenia, potentially impairing immunotherapy efficacy. As the skull bone marrow has recently been identified as a key hematopoietic site, this study evaluated the impact of skull RT dose on HTs in NSCLC patients undergoing cranial RT and immunotherapy.
Wed, 24 Dec 2025 00:00:00 -0800 Editor's Note Wed, 24 Dec 2025 00:00:00 -0800 Enhancing Radiotherapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131 While radiation therapy quality assurance (RTQA) is important in any clinical trial with a radiation therapy (RT) component, it is paramount in lymphoma trials for several reasons. As lymphoma RT has evolved to utilize smaller and more complex treatment fields such as involved-site radiation therapy (ISRT) and PET-directed residual site radiation therapy (pRSRT), accurate target delineation has become more challenging, especially when lymphoma patients comprise only a small proportion of most radiation oncologists’ clinical practice.
Wed, 24 Dec 2025 00:00:00 -0800 Prevalence and Prognostic Value of Individual T4-defining Radiologic Features in HPV-Positive Oropharyngeal Carcinoma To report the prevalence, validity, and relative prognostic value of specific UICC/AJCC T4-defining radiological features in HPV-positive oropharyngeal squamous cell carcinoma (HPV+ OPSCC).
Tue, 23 Dec 2025 00:00:00 -0800 STEREOTACTIC BODY RADIOTHERAPY (SBRT) BOOST FOLLOWING URGENT 3D CONFORMAL RADIOTHERAPY FOR METASTATIC EPIDURAL SPINAL CORD COMPRESSION (MESCC): A PHASE 1 FEASIBILITY STUDY Palliative 3D-conformal radiotherapy (3DCRT) is the standard treatment for metastatic epidural spinal cord compression (MESCC) in non-surgical candidates, but pain, motor and neurologic outcomes are variable. We conducted a pilot study to determine feasibility of stereotactic body radiotherapy (SBRT) boost following 3D-CRT and characterize impact on outcomes.
Tue, 23 Dec 2025 00:00:00 -0800 Compensatory Hypertrophy and Changes of Liver Function after Sequential TACE, SBRT and Immunotherapy (START-FIT) in Unresectable Hepatocellular Carcinoma Sequential trans-arterial chemoembolization, stereotactic body radiotherapy and immunotherapy (START-FIT) has shown its promising potential as a downstaging therapy of unresectable HCC. This study aims at analysing the dynamic changes of liver volume and hepatic function following START-FIT.
Tue, 23 Dec 2025 00:00:00 -0800 A prospective phase II trial of hypofractionated stereotactic radiotherapy (FSRT) for patients with 1-10 brain metastases from breast cancer While fractionated stereotactic radiotherapy (FSRT) remains understudied for the management of breast cancer brain metastases(BCBM), this study aimed to investigate its therapeutic efficacy and safety in the context of contemporary systemic therapies. We enrolled patients with 1–10 brain lesions.
Tue, 23 Dec 2025 00:00:00 -0800 Safety and feasibility of stereotactic body radiation therapy for patients with hepatocellular carcinoma and advanced cirrhosis awaiting liver transplantation: A prospective pilot clinical trial Liver transplantation is the definitive treatment for hepatocellular carcinoma (HCC) in eligible patients with cirrhosis. Bridging liver-directed therapies (LDTs) are critical for maintaining transplant eligibility during long wait-times. However, due to the fear of decompensation, many advanced cirrhotic patients are excluded from receiving LDTs. This prospective pilot clinical trial evaluated the feasibility, safety, and efficacy of stereotactic body radiation therapy (SBRT) as a bridging therapy in an advanced cirrhotic HCC population.
Mon, 22 Dec 2025 00:00:00 -0800 High dose REirradiation for in-field recurrent Lung Cancer in the THOrax (RETHO): outcomes of a phase 2 prospective clinical trial Locoregional failures after (chemo)radiotherapy for primary lung cancer account for 30% of relapses. Reirradiation in this setting is challenging. To evaluate the outcome after thoracic reirradiation with radical doses, a prospective phase 2 trial was conducted for marginal or in-field recurrences of lung cancer.
Sat, 20 Dec 2025 00:00:00 -0800 A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD) PD-1 inhibitors have improved metastatic non-small cell lung cancer (NSCLC) prognosis. Stereotactic ablative body radiotherapy (SABR) may enhance immunity. This study evaluated the activity and safety of adding SABR to first-line immunotherapy post chemotherapy with nivolumab for metastatic NSCLC.
Fri, 19 Dec 2025 00:00:00 -0800 Multi-Institutional Analysis of MR-Guided Single-Fraction Stereotactic Ablative Body Radiation Therapy: Feasibility, Safety, and Efficacy Stereotactic ablative body radiation therapy (SABR) is commonly delivered in multiple fractions, whereas single-fraction (SF) SABR remains uncommon. Magnetic resonance (MR) guided linacs provide superior soft-tissue contrast compared to cone-beam computed tomography on conventional linacs, online adaptive replanning, continuous intrafraction visualization, and automatically triggered beam delivery, potentially enabling safe and effective SF-SABR.
Fri, 19 Dec 2025 00:00:00 -0800 Initiating proton ocular treatments on general-purpose beamlines: Challenges and trends from the survey of USA facilities Historically, ocular melanomas and other eye cancers accounted for a substantial share of proton therapy patients. Although the number of proton facilities in the USA increased rapidly in the last decade, as of 2025, only roughly 1 out of 6 had active ocular proton therapy (OPT) programs. Despite the robust growth in the number of proton treatments overall, eye treatments in the USA appear to have peaked in 2016.
Fri, 19 Dec 2025 00:00:00 -0800 Erratum to: 2025 ROECSG Spring Symposium Abstracts [Int J of Radiat Oncol Biol Phys 2025:123, e2-e7] It has come to the publisher’s attention that one abstract from the 2025 ROECSG symposium abstracts was inadvertently left out due to a technical error.
Fri, 19 Dec 2025 00:00:00 -0800 Qualitative Blinded Clinical Assessment of Automated and Manual IMPT Plans for Head and Neck Cancer To clinically validate fully automated intensity-modulated proton therapy (IMPT) planning for head and neck cancer (HNC) through blinded comparison with manual plans by experienced radiation oncologists (ROs).
Fri, 19 Dec 2025 00:00:00 -0800 “Mesenchymal stem cell treatment of cutaneous radiation injury” Regenerative medicine is an emerging field of medicine focusing on development of novel therapies to repair, replace, or regenerate damaged cells and tissues. Mesenchymal stem cell (MSC) use to promote tissue repair in a variety of injury and disease states, is one promising area of regenerative medicine. Herein we review the fundamental stem cell biology of MSCs, their use in treatment of radiation injury to internal organs, cutaneous injury and specifically, cutaneous radiation injury. We also highlight publicly available clinical case reports where MSCs have been used in treatment of acute cutaneous radiation injury.
Wed, 17 Dec 2025 00:00:00 -0800 |
|
|
| ||
|
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
The noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib achieved noninferiority to the covalent BTK inhibitor ibrutinib in terms of overall response rate in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to findings from a randomized... Tuesday, December 9, 2025 11:00 AM GLP-1 RAs May Have Little or No Effect on the Risk of Obesity-Related Cancers The development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has revolutionized the management of obesity and type 2 diabetes. The agents offer therapeutic potential in a host of other conditions, including cardiovascular, liver, and neurodegenerative diseases, as well as the... Deb Schrag, MD, MPH, FASCO, Elected 2027–2028 ASCO President On December 19, 2025, ASCO announced its members had elected Deb Schrag, MD, MPH, FASCO, as President for the 2027–2028 term. Dr. Schrag will begin her term as President-Elect following the conclusion of the 2026 ASCO Annual Meeting. NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer Circulating tumor DNA (ctDNA) levels may help to determine which patients with colon cancer could benefit from the addition of nonsteroidal anti-inflammatory drugs (NSAIDs), such as celecoxib, to chemotherapy following surgery, according to findings from a post hoc analysis of the CALGB/SWOG 80702... Thursday, December 18, 2025 5:00 PM Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns Researchers have uncovered that sex-specific dysregulation of exosomal non-coding RNAs may drive different patterns of disease progression of multiple myeloma in male and female individuals, according to findings published in Blood Cancer Journal. Friday, December 19, 2025 11:00 AM Data Published on Incidence of Immune Checkpoint Inhibitor–Associated ITP Researchers have published valuable information about a rare but serious complication of cancer immunotherapy, providing the first large-scale description of its risk factors and clinical course and underscoring the importance of early diagnosis and treatment. The findings were published by Leaf et ... Thursday, December 18, 2025 10:14 AM Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma A higher absolute lymphocyte count (ALC) after receipt of chimeric antigen receptor (CAR) T-cell therapy may be associated with improved progression-free and/or overall survival in patients with non-Hodgkin lymphoma, according to findings from the 2025 American Society of Hematology (ASH) Annual... Thursday, December 18, 2025 12:30 PM CD123-Targeting ADC Shows Activity in AML and BPDCN Researchers presented new data from two ongoing studies of pivekimab sunirine, an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 2025 American Society of Hematology (ASH) Annual Meeting & Exposition. Thursday, December 18, 2025 8:47 AM Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS A multicenter trial led by investigators at The University of Texas MD Anderson Cancer Center demonstrated that a 5-day regimen of azacitidine provides the best balance of efficacy and safety for patients with lower-risk myelodysplastic syndromes (MDS). The researchers compared three abbreviated... Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL Initial results from the phase III GIMEMA ALL2820 trial demonstrated that a front-line, chemotherapy-free regimen combining the tyrosine kinase inhibitor (TKI) ponatinib and the bispecific T-cell engager blinatumomab significantly outperformed a standard treatment strategy of imatinib plus... Intravesical Cretostimogene Grenadenorepvec Shows Strong High-Grade Recurrence-Free Survival in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer Intravesical Oncolytic Adenovirus Delivers High Complete Response Rates in BCG-Naive, High-Risk, Non–Muscle-Invasive Bladder Cancer With Carcinoma in Situ Neoadjuvant SABR Improves Outcomes in Patients With Renal Cell Carcinoma and IVC Tumor Thrombus Tumor thrombus in the inferior vena cava (IVC) resulting from renal cell carcinoma (RCC) can be safely and effectively treated with stereotactic ablative radiation therapy (SABR) prior to surgery, according to findings from a phase II trial presented at the 26th Annual Meeting of the Society of... IMvigor011 Subgroup Analysis: Role of ctDNA in Guiding Adjuvant Treatment for Muscle-Invasive Bladder Cancer Circulating tumor DNA (ctDNA) status after radical cystectomy may be able to effectively guide adjuvant treatment decisions for patients with muscle-invasive bladder cancer, according to data presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO).1 KEYNOTE-905: Perioperative Immunotherapy Regimen Active in Cisplatin-Ineligible MIBC A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response rates compared to radical cystectomy alone in patients with muscle-invasive bladder... Gemcitabine Intravesical System Shows High Disease-Free Survival Rates in BCG-Unresponsive Papillary-Only NMIBC Monotherapy with a gemcitabine intravesical system (TAR-200; Gem-iDRS) demonstrated high disease-free survival rates in patients with bacillus Calmette-Guérin (BCG)-unresponsive papillary-only high-risk non–muscle-invasive bladder cancer (NMIBC), according to data presented at the 26th Annual... Distant Disease–Free Survival as a Surrogate for Overall Survival in Trials of Neoadjuvant Therapy in Early Breast Cancer In a pooled analysis of randomized neoadjuvant trials reported in The Lancet Oncology, Conforti et al found that distant disease–free survival was a “robust” surrogate endpoint for overall survival in many patients with early breast cancer. FDA Approves Durvalumab With FLOT for Resectable Gastric/GEJ Adenocarcinoma On November 25, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab, for the treatment of adult... Tuesday, November 25, 2025 2:30 PM 10-Year Outcomes With Adjuvant Metronomic Capecitabine in Early Triple-Negative Breast Cancer In a 10-year update of a Chinese phase III trial (SYSUCC-001) reported in The Lancet Oncology, Yuan et al found that the sequential addition of metronomic capecitabine to standard adjuvant therapy continued to be associated with significant benefits in patients who had undergone surgery for early... FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection On December 17, the U.S. Food and Drug Administration (FDA) approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant). Thursday, December 18, 2025 9:50 AM FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer On December 17, the U.S. Food and Drug Administration (FDA) approved the PARP inhibitor rucaparib (Rubraca) for adults with deleterious BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer previously treated with an androgen receptor–directed therapy.... Wednesday, December 17, 2025 9:20 PM Community Oncology Report Showcases Barriers to Therapy Access, Staffing, and Clinical Trial Participation A report recently released by McKesson on the state of community oncology highlights the current challenges facing physicians, administrators, and clinical staff who work in community practices. Wednesday, December 17, 2025 10:15 AM FDA Approves CAR T-Cell Therapy for Relapsed/Refractory Marginal Zone Lymphoma On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved the CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least two prior... Friday, December 5, 2025 10:45 AM Addition of Eflornithine to Lomustine in Patients With Recurrent Grade 3 Astrocytoma As reported in the Journal of Clinical Oncology by Colman et al, the phase III STELLAR trial showed no difference in overall survival with the addition of eflornithine to lomustine in patients with recurrent grade 3 astrocytoma; however, marked progression-free survival and overall survival... Preoperative PAXG vs mFOLFIRINOX in Pancreatic Ductal Adenocarcinoma As reported in The Lancet by Reni et al, analysis of the first randomization in an Italian 2 × 2 factorial phase III trial (PACT-21 CASSANDRA) has shown better event-free survival with preoperative PAXG (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) vs mFOLFIRINOX (modified fluorouracil,... Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced NSCLC As reported in the Journal of Clinical Oncology by Tomasini et al, findings in a cohort of the early-phase CHRYSALIS-2 trial indicate activity of amivantamab plus lazertinib in patients with atypical EGFR-mutated advanced non–small cell lung cancer (NSCLC). |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer
Despite radical cystectomy, residual urothelial cancer cells can persist undetected in patients with muscle-invasive bladder cancer, silently seeding future relapse. New data from the phase III IMvigor011 trial demonstrate that circulating tumour DNA (ctDNA) can be used to effectively stratify patients by recurrence risk, enabling adjuvant atezolizumab to be delivered selectively to those who are likely to benefit. This precision ctDNA-guided strategy might fundamentally reshape postoperative management through alignment of treatment intensity with molecular risk. Mon, 15 Dec 2025 00:00:00 -0800 The global epidemiology of acute myeloid leukaemia Despite the availability of various novel therapies, the global incidence of acute myeloid leukaemia (AML) has continued to increase. Owing to a combination of population ageing and more effective diagnosis, AML remains much more common in economically developed countries. Conversely, AML is less common in the economically developing world, albeit often with worse outcomes owing to a lack of access to effective therapies. In this Review, the authors describe these global trends as well as their underlying reasons, including the changing landscape of risk factors, demographic disparities and differing treatment outcomes. Fri, 05 Dec 2025 00:00:00 -0800 When ctDNA says ‘maybe’: improving the dynamics of MRD trials Circulating tumour DNA (ctDNA) has emerged as a promising biomarker enabling the detection of minimal residual disease (MRD) in patients with locally advanced colon cancer. The phase II/III DYNAMIC-III trial, with results recently reported, is a landmark effort to evaluate ctDNA-guided adjuvant treatment in this setting. Here, I discuss how, despite not yet changing clinical practice, these results provide essential insights to guide the next generation of ctDNA-driven trials. Mon, 01 Dec 2025 00:00:00 -0800 The development of CAR T cells for patients with CNS malignancies Despite advances in the treatment of many advanced-stage solid tumours, the outcomes of patients with central nervous system tumours have not improved substantially for several decades, largely owing to a lack of novel therapies. In this Review, the authors describe the clinical experience with chimeric antigen receptor T cells both in adults and children with these historically difficult to treat malignancies, including some promising signals of efficacy. Mon, 01 Dec 2025 00:00:00 -0800 Towards biomarker-driven therapies for urothelial carcinoma The identification of prognostic and predictive biomarkers for immune checkpoint inhibitors, antibody–drug conjugates and targeted therapies for urothelial carcinoma is currently an active area of research. In this setting, circulating tumour DNA is emerging as a minimally invasive biomarker with utility for monitoring clinical responses. The authors of this Review discuss biomarkers that could have clinical utility in patients with this malignancy Thu, 27 Nov 2025 00:00:00 -0800 Personalized intensification of treatment for hormone-sensitive prostate cancer Advances in the management of hormone-sensitive prostate cancer have been achieved through intensification of therapy, although careful patient selection is required. In this Review, the authors discuss personalized treatment strategies for both non-metastatic and metastatic hormone-sensitive prostate cancer, as well as emerging novel therapies and key principles for toxicity mitigation. Thu, 27 Nov 2025 00:00:00 -0800 AI and human expertise in cancer care — striving for synergy Artificial intelligence (AI) excels at rapid data synthesis and pattern recognition, yet the practice of oncology demands nuanced clinical judgement, ethical reasoning and authentic empathy — qualities only humans can provide. The future of cancer care lies in synergy: AI augmenting human expertise, not replacing it. Excellence emerges when computational power meets clinical wisdom. Tue, 25 Nov 2025 00:00:00 -0800 Could a COVID-19 vaccine improve the effectiveness of cancer immunotherapy? A recent Nature article reports that mRNA vaccines against SARS-CoV-2 confer improved survival among patients with advanced-stage non-small-cell lung cancer or melanoma receiving immune-checkpoint inhibitors owing to activation of systemic immunity, potentiating antitumour responses. This retrospective proof-of-principle study indicates the potential for combined therapeutic interventions, although both the timing of vaccination as well as the nature of the elicited immune responses requires further investigation. Thu, 20 Nov 2025 00:00:00 -0800 |
|
| ||
|
Development of a predictive model for lymph node metastasis in esophageal cancer using 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) semi-quantitative parameters and tumor biomarkers
Vol 16, No 6 (December 31, 2025): 2515-2526 Survival analysis of small cell carcinoma of the esophagus: a 15-year retrospective study from a high-incidence region Vol 16, No 6 (December 31, 2025): 2527-2538 First-line PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for advanced esophageal and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials Vol 16, No 6 (December 31, 2025): 2539-2552 The clinical efficacy and pathological assessment of neoadjuvant imatinib treatment in patients with primary gastrointestinal stromal tumors Vol 16, No 6 (December 31, 2025): 2553-2564 mTLS status predicts survival benefit from adjuvant chemotherapy in gastric cancer patients treated with neoadjuvant therapy and surgery Vol 16, No 6 (December 31, 2025): 2565-2583 Trifluridine/tipiracil (FTD/TPI) in advanced gastric cancer—a retrospective cohort study providing real-world survival and safety data from the United Kingdom Vol 16, No 6 (December 31, 2025): 2584-2591 Parenteral nutrition versus enteral nutrition after gastric cancer surgery: a systematic review and meta-analysis of randomized controlled trials Vol 16, No 6 (December 31, 2025): 2592-2602 Trends of mortality among patients with malignant neoplasms of digestive system in the United States from 2007 to 2021 Vol 16, No 6 (December 31, 2025): 2603-2612 The effect of neoadjuvant chemoradiotherapy on perioperative outcomes in rectal cancer patients following stoma reversal—a retrospective cohort analysis Vol 16, No 6 (December 31, 2025): 2613-2619 The optimal number of lymph nodes examined for rectal cancer patients undergoing neoadjuvant long-course chemoradiotherapy Vol 16, No 6 (December 31, 2025): 2620-2631 Predicting bevacizumab efficacy: the emerging role of ACTL6B in colorectal cancer Vol 16, No 6 (December 31, 2025): 2632-2650 A prognostic nomogram for colorectal cancer: integrating blood microbiome and clinical factors Vol 16, No 6 (December 31, 2025): 2651-2663 Bibliometric analysis on the correlation between colorectal cancer and tumor microenvironment [2009–2024] Vol 16, No 6 (December 31, 2025): 2664-2685 Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: a systematic review and meta-analysis Vol 16, No 6 (December 31, 2025): 2686-2702 ZNF454-FSTL3 axis inhibits colorectal cancer progression by inhibiting HIF-1α-mediated glycolysis in hypoxia Vol 16, No 6 (December 31, 2025): 2703-2718 Glutaryl-CoA dehydrogenase: a key biomarker linking lysine degradation to hepatocellular carcinoma metastasis and prognosis via NF-KB signaling pathway Vol 16, No 6 (December 31, 2025): 2719-2730 Safety and efficacy of transcatheter chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable primary liver cancer: a single-center prospective study Vol 16, No 6 (December 31, 2025): 2731-2740 Efficacy and safety of tyrosine kinase inhibitors combined with sintilimab and transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma: a pooled analysis Vol 16, No 6 (December 31, 2025): 2741-2749 Predicting the prognosis of hepatocellular carcinoma after curative resection using a nomogram based on the ratio of prealbumin to platelet distribution width Vol 16, No 6 (December 31, 2025): 2750-2774 Revisiting the role of postoperative adjuvant transarterial chemoembolization in hepatocellular carcinoma: a propensity score matching analysis Vol 16, No 6 (December 31, 2025): 2775-2788 Survival outcomes of patients after liver transplantation for patients with hepatocellular carcinoma exceeding the Hangzhou criteria Vol 16, No 6 (December 31, 2025): 2789-2801 Landscape targeted of therapy in advanced pancreatic adenocarcinoma: a network meta-analysis of randomized controlled trials [2010–2024] Vol 16, No 6 (December 31, 2025): 2802-2813 Metformin reshapes the tumor microenvironment and enhances prognosis in invasive pancreatic ductal adenocarcinoma with diabetes mellitus Vol 16, No 6 (December 31, 2025): 2814-2826 The value of lipid metabolism-related genes in pancreatic cancer immunotherapy and drug prediction Vol 16, No 6 (December 31, 2025): 2827-2846 Lumbar centroid level subcutaneous fat volume increased performance of prognostic predictive model in digestive system cancers: a real-world cohort study Vol 16, No 6 (December 31, 2025): 2847-2863 Hypercalcemia in metastatic pancreatic neuroendocrine tumor: a case report of ectopic 1,25 hydroxyvitamin D production by tumor cells and tumor-associated macrophages Vol 16, No 6 (December 31, 2025): 2864-2872 Staged approach to overcome hyperbilirubinemia: tailored chemotherapy in liver metastases-a case report Vol 16, No 6 (December 31, 2025): 2873-2880 Multidisciplinary team approach of treatment of a metastatic gastric carcinoma during pregnancy: a case report Vol 16, No 6 (December 31, 2025): 2881-2886 Intraocular metastasis from an anal squamous cell carcinoma: a case report Vol 16, No 6 (December 31, 2025): 2887-2890 Claudin 18.2 in gastroesophageal adenocarcinoma: prevalence, biomarker associations, and implications for equity Vol 16, No 6 (December 31, 2025): 2891-2894 Right place right time: the role of immunotherapy in patients with locally advanced gastric/gastroesophageal junction adenocarcinoma Vol 16, No 6 (December 31, 2025): 2895-2899 Potential of regorafenib in late-line treatment for refractory advanced gastric cancer Vol 16, No 6 (December 31, 2025): 2900-2904 Erratum: The clinical value of spectral computed tomography reconstruction technology for the anatomy of the superior mesenteric artery in laparoscopic radical right hemicolectomy for colon cancer: a cross-sectional study Vol 16, No 6 (December 31, 2025): 2905-2906 |
|
|
|
| ||
|
The Michigan Appropriateness Guide for Intravenous Catheters in Adult Patients With Cancer (MAGIC-ONC): Results From a Multispecialty Panel Using the RAND/UCLA Appropriateness Method
Annals of Internal Medicine, Volume 178, Issue 12_Supplement, Page S143-S177, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Trends in Cancer Incidence in Younger and Older Adults Annals of Internal Medicine, Volume 178, Issue 12, Page 1677-1687, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Primary Care Physician Time Spent in Patient Care: An Observational Study Using Electronic Health Record Logs Annals of Internal Medicine, Volume 178, Issue 12, Page 1688-1697, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Trends in and Predictors of Physician Attrition From Clinical Practice Across Specialties Annals of Internal Medicine, Volume 178, Issue 12, Page 1698-1708, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 The Mediterranean Diet for Irritable Bowel Syndrome Annals of Internal Medicine, Volume 178, Issue 12, Page 1709-1717, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Step Accumulation Patterns and Risk for Cardiovascular Events and Mortality Among Suboptimally Active Adults Annals of Internal Medicine, Volume 178, Issue 12, Page 1718-1727, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Effectiveness of Recombinant Herpes Zoster Vaccine in the U.S. Medicare Population, 2018 to 2019, by Immunocompetence and Prior Receipt of Live Zoster Vaccine Annals of Internal Medicine, Volume 178, Issue 12, Page 1728-1736, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Palliative Care Educational App for Family Caregivers of Homebound Patients With Incurable Cancer Annals of Internal Medicine, Volume 178, Issue 12, Page 1737-1751, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Effectiveness of Psychological Therapies for Depression During the Perinatal Period Annals of Internal Medicine, Volume 178, Issue 12, Page 1752-1762, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Artificial Intelligence–Assisted Data Extraction With a Large Language Model: A Study Within Reviews Annals of Internal Medicine, Volume 178, Issue 12, Page 1763-1771, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 How Would You Manage This Diabetic Patient With a Foot Infection? Grand Rounds Discussion From Beth Israel Deaconess Medical Center Annals of Internal Medicine, Volume 178, Issue 12, Page 1785-1792, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Ethical Issues in Organ Transplantation: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 178, Issue 12, Page 1772-1778, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Quality Indicators for Screening and Surveillance of Colorectal Cancer in Adults: A Review of Performance Measures by the American College of Physicians Annals of Internal Medicine, Volume 178, Issue 12, Page 1779-1784, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Immigration Enforcement Tactics and Systemic Health Harms: The Ethical Imperative for Medical Advocacy Annals of Internal Medicine, Volume 178, Issue 12, Page 1793-1795, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Payment for Physician Services in the United States: Has a Reckoning Begun? Annals of Internal Medicine, Volume 178, Issue 12, Page 1796-1797, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Overdue: Delayed Revision of Institutional Review Board Policies Characterizing Pregnant Women After the Revised Common Rule Annals of Internal Medicine, Volume 178, Issue 12, Page 1798-1800, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Generations at Risk: Unveiling the Global Increase in Cancer at Both Ends of Adulthood Annals of Internal Medicine, Volume 178, Issue 12, Page 1801-1802, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Stepping Up Our Game: Longer Bouts of Activity to Boost Longevity Annals of Internal Medicine, Volume 178, Issue 12, Page 1803-1804, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Patient Q Annals of Internal Medicine, Volume 178, Issue 12, Page 1805-1806, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Beyond the Diagnosis: Finding the Person in the Patient Annals of Internal Medicine, Volume 178, Issue 12, Page 1807, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Patient Portal Panic Annals of Internal Medicine, Volume 178, Issue 12, Page 1808-1809, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 TMI Annals of Internal Medicine, Volume 178, Issue 12, Page 1810-1811, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Revision of Research Abstracts Through the Editorial Process Annals of Internal Medicine, Volume 178, Issue 12, Page 1813-1816, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Trends in Dispensed Gabapentin Prescriptions in the United States, 2010 to 2024 Annals of Internal Medicine, Volume 178, Issue 12, Page 1816-1818, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Changes in Carbapenemase-Producing Carbapenem-Resistant Enterobacterales, 2019 to 2023 Annals of Internal Medicine, Volume 178, Issue 12, Page 1818-1821, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 Management of Hyperglycemia in Hospitalized Patients Annals of Internal Medicine, Volume 178, Issue 12, Page 1821-1822, December 2025. <br/> Tue, 04 Nov 2025 08:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
| ||
|
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study
Insmed pointed to a strong placebo response as the reason for the trial’s failure.
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression In a first for the Parkinson’s field, AC Immune’s immunotherapy has stabilized key biomarkers that suggest an effect on the disease’s course.
Structure Stock Soars as Oral GLP-1 Generates ‘Highly Competitive’ Weight Loss Structure’s aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech’s stock up nearly 103% as markets closed on Monday.
Dyne’s Exon Skipper Delivers ‘Best Ever’ Functional Outcomes in Early DMD Study Dyne’s exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the “best ever” for this treatment class, Stifel analysts said.
Bridging Formulation and Device: Integrated Supply Chain Strategies for U.S. Pharma Manufacturing The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development with drug delivery device design—and leveraging a single‐vendor ecosystem—can deliver significant time, cost, and regulatory advantages for US‑focused drug products, according to industry experts. Praxis Ends Epilepsy Study Early Due to Strong Results, Heads to FDA Praxis Precision Medicines has also announced a “successful” pre-NDA meeting with the FDA for its essential tremor drug candidate ulixacaltamide, for which an approval application is slated for early 2026.
Imvax Heads to FDA With 6-Month Survival Gain in Glioblastoma, Despite Endpoint Miss While Imvax’s autologous immunotherapy IGV-001 missed the primary endpoint of progression-free survival in a Phase IIb trial, the company will request a meeting with the FDA to discuss next steps for “synergistic” treatment.
Novo Bounces Back With ‘Competitive’ Mid-Stage Weight Loss Data for Amycretin Novo Nordisk’s amycretin showed no weight-loss plateau over 36 weeks in patients with type 2 diabetes, suggesting its efficacy could become even stronger with longer follow-up, according to analysts at BMO Capital Markets.
NervGen’s Peptide Achieves Nervous System Repair in Phase II Spinal Cord Injury Study NervGen will meet with the FDA early next year to align on a regulatory path forward for NVG-291 in chronic spinal cord injury.
J&J, Contineum Fail ‘Risky’ Mid-Stage Multiple Sclerosis Trial While expressing disappointment, William Blair analysts were unsurprised by the Phase II failure, having assigned the VISTA study a high level of risk given the “mixed” performance of a similar drug in a prior multiple sclerosis study.
Caliway’s Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus Hope Biosciences Research Foundation Reports Promising Phase II Trial Results for Stem Cell Therapy in Parkinson’s Disease Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain Promontory Therapeutics Announces Interim Efficacy Requirement Reached on Phase 2 Study of PT-112 Monotherapy in Patients with Recurrent Thymoma Imviva Biotech Announces First Patient Dosed in Phase 1b/2 TENACITY-01 Trial of CTD402 CAR-T Cell Therapy T-MAXIMUM Pharmaceutical’s Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP) Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 Werewolf Therapeutics Announces Pipeline and Business Updates Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet’s Disease Published in Rheumatology (Oxford) |
Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial
Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine’s valuation.
AstraZeneca’s ATR Inhibitor Fails to Improve Survival in Phase III Lung Cancer Trial Ceralasertib is part of AstraZeneca’s ambitious plan to hit $80 billion in revenue by 2030.
Takeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data With zasocitinib, Takeda is looking to challenge Bristol Myers Squibb’s kinase inhibitor Sotyktu, for which the Japanese pharma is running a head-to-head study in plaque psoriasis. Takeda expects to file for zasocitinib’s FDA approval next year.
Lilly’s Obesity Pill Maintains Weight Loss as Estimated Approval Timelines Inch Closer Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.
Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key secondary endpoints in the pivotal RINGSIDE trial. Immunome is planning an FDA application for the second quarter of 2026.
Argenyx’s Vyvgart Flops Phase III Thyroid Eye Disease Test, Raising Risk for Ongoing Trials Vyvgart, an FcRn inhibitor already approved for generalized myasthenia gravis, is also being tested in myositis, Sjögren’s disease and the “clinically related” Graves disease.
Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.
‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT modality, including from GSK, Merck and Roche.
Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called dysesthesia, has emerged in the late-stage TRIUMPH-4 trial.
Bridging Formulation and Device: Integrated Supply Chain Strategies for U.S. Pharma Manufacturing The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development with drug delivery device design—and leveraging a single‐vendor ecosystem—can deliver significant time, cost, and regulatory advantages for US‑focused drug products, according to industry experts. Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus Secura Bio Provides Corporate Update and Highlights Progress in its Phase 3 TERZO Study Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions Tolmar Announces Expanded Indication for Rubraca® (rucaparib) First and Only PARP Inhibitor to Outperform Docetaxel in a Head-to-Head Phase 3 Trial Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial |
Neurocrine’s Valbenazine Fails Phase III Neurodevelopmental Disorder Trial
Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine’s valuation.
Pfizer Reports Patient Death in Long-Term Trial of Hympavzi for Hemophilia A The patient, who died on December 14, was originally enrolled in a Phase III study in 2022 and transitioned into an extension phase in 2023.
AstraZeneca’s ATR Inhibitor Fails to Improve Survival in Phase III Lung Cancer Trial Ceralasertib is part of AstraZeneca’s ambitious plan to hit $80 billion in revenue by 2030.
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study Insmed pointed to a strong placebo response as the reason for the trial’s failure.
Patient Deaths Put Merck, Daiichi Sankyo’s Antibody-Drug Conjugate on Hold The fatalities were attributed to interstitial lung disease, a known side effect of Daiichi Sankyo’s DXd-based antibody-drug conjugates. A spokesperson declined to say how many patients died.
Takeda’s $4B Nimbus Bet Pays Off With ‘Best-in-Class’ Phase III Plaque Psoriasis Data With zasocitinib, Takeda is looking to challenge Bristol Myers Squibb’s kinase inhibitor Sotyktu, for which the Japanese pharma is running a head-to-head study in plaque psoriasis. Takeda expects to file for zasocitinib’s FDA approval next year.
Lilly’s Obesity Pill Maintains Weight Loss as Estimated Approval Timelines Inch Closer Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.
Uptick in Dealmaking, Chinese Partnerships Drive Biotech’s Comeback Biotech’s slump may finally be over in 2026. In interviews with BioSpace, Zymeworks’ CEO Ken Galbraith and Zai Lab’s President and COO Josh Smiley explain what’s fueling the comeback.
Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key secondary endpoints in the pivotal RINGSIDE trial. Immunome is planning an FDA application for the second quarter of 2026.
Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta QurAlis Confirms Signal of Target Engagement in ALS Patients in Phase 1 Clinical Trial of QRL-101, a Potentially Best-in-Class Selective Kv7.2/7.3 Ion Channel Opener SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma Caliway’s Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study |
|
| ||
|
FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection
On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
Wed, 17 Dec 2025 00:00:01 -0800
FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).
Wed, 17 Dec 2025 00:00:01 -0800
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.
Mon, 15 Dec 2025 00:00:01 -0800
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.
Fri, 12 Dec 2025 00:00:01 -0800
FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy
Thu, 04 Dec 2025 00:00:01 -0800
FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Wed, 03 Dec 2025 00:00:01 -0800
FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma On November 25, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Tue, 25 Nov 2025 00:00:01 -0800
FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin.
Fri, 21 Nov 2025 00:00:01 -0800
FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.
Wed, 19 Nov 2025 00:00:01 -0800
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Wed, 19 Nov 2025 00:00:01 -0800
FDA grants traditional approval to daratumumab and hyaluronidase-fihj for newly diagnosed light chain amyloidosis On November 19, 2025, the Food and Drug Administration granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. FDA granted accelerated approval for this indication in 2021.
Wed, 19 Nov 2025 00:00:01 -0800
FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas On November 19, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
Wed, 19 Nov 2025 00:00:01 -0800
FDA approves epcoritamab-bysp for follicular lymphoma indications On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024).
Tue, 18 Nov 2025 00:00:01 -0800
FDA approves new interchangeable biosimilar to Perjeta On November 13, 2025, the Food and Drug Administration approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) as an interchangeable biosimilar to Perjeta (pertuzumab, Genentech Inc.). This is the first approval of a biosimilar for Perjeta.
Thu, 13 Nov 2025 00:00:01 -0800
FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.
Thu, 13 Nov 2025 00:00:01 -0800
FDA approves daratumumab and hyaluronidase-fihj for high-risk smoldering multiple myeloma On November 6, 2025, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) for adults with high-risk smoldering multiple myeloma (SMM).
Thu, 06 Nov 2025 00:00:01 -0800
FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation On October 24, 2025, the Food and Drug Administration approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
Fri, 24 Oct 2025 00:00:01 -0700
FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma On October 23, 2025, the Food and Drug Administration approved belantamab mafodotin-blmf (Blenrep, GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Thu, 23 Oct 2025 00:00:01 -0700
FDA approves cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinoma On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation.
Wed, 08 Oct 2025 00:00:01 -0700
FDA approves lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancer On October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.
Thu, 02 Oct 2025 00:00:01 -0700
FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company), an estrogen receptor antagonist, for adults with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Thu, 25 Sep 2025 00:00:01 -0700
FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection On September 19, 2025, the Food and Drug Administration approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab (Keytruda, Merck). See the prescribing information for the specific indications.
Fri, 19 Sep 2025 00:00:01 -0700
FDA approves selumetinib for pediatric patients 1 year of age and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas On September 10, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) granules and capsules for pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules for pediatric patients 2 years of age and older with NF1 who have symptomatic, inoperable PN.
Wed, 10 Sep 2025 00:00:01 -0700
FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Gemcitabine intravesical system is co-packaged with a urinary catheter and stylet used for insertion through the urinary catheter into the bladder.
Tue, 09 Sep 2025 00:00:01 -0700
|
|
|